stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Revenue growth
Scholar Rock Holding Corporation's revenue growth over the twelve months to 31 March 2022 was 213.7%. Over the past ten years it has ranged from −98.2% (fiscal 2016) to 5,306.9% (fiscal 2019); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2022 | 76.4% | 54.25 |
| FY2021 | 22.2% | 46.99 |
| FY2020 | −24.8% | (5,331.69) |
| FY2019 | 5,306.9% | 5,405.01 |
| FY2016 | −98.2% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Mar 2022 | 605.0% | 587.19 |
| Dec 2021 | 17.8% | (62.07) |
| Sep 2021 | 79.9% | 62.09 |
| Jun 2021 | 17.8% | 24.22 |
| 9 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CGON CG Oncology, Inc. compare | 840.8% |
| SRRK Scholar Rock Holding Corporation | 213.7% |
| COGT Cogent Biosciences, Inc. compare | 110.2% |
| PTCT PTC Therapeutics, Inc. compare | −35.1% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement